Clinical impact of circulating tumor DNA to track minimal residual disease in colorectal cancer patients. Hopes and limitations
Charbel Soueidy, Aziz Zaanan, Maximiliano Gelli, Émilie Moati, Claire Gallois, Valérie Taly, Pierre Laurent‐Puig, Léonor Benhaïm, Julien Taı̈eb
Abstract
•ctDNA is a strong predictor of recurrence un CRC patients after curative surgery.•ctDNA is a promising biomarker to select patients with resected colon cancer for adjuvant chemotherapy.•ctDNA analysis methods should be chosen adequately to fit the goal of a personalized treatment approach. Circulating tumor DNA (ctDNA) has been studied as a non-invasive tool for disease monitoring in different cancer types. Despite advances in colorectal cancer (CRC) management, it remains a leading cause of mortality and there is an unmet need for new biomarkers to guide therapeutic approaches and improve patient’s outcome after surgical resection of the primary tumor or its metastatic sites. This review summarizes the different clinical results and ongoing studies on the performances of ctDNA as a prognostic marker for disease recurrence, both in non-metastatic patients with resection of the primary tumor and in those with full resection of metastatic disease. Circulating tumor DNA (ctDNA) has been studied as a non-invasive tool for disease monitoring in different cancer types. Despite advances in colorectal cancer (CRC) management, it remains a leading cause of mortality and there is an unmet need for new biomarkers to guide therapeutic approaches and improve patient’s outcome after surgical resection of the primary tumor or its metastatic sites. This review summarizes the different clinical results and ongoing studies on the performances of ctDNA as a prognostic marker for disease recurrence, both in non-metastatic patients with resection of the primary tumor and in those with full resection of metastatic disease.